EDX Medical Group PLC General Meeting results (2978R)

TIDMEDX

RNS Number : 2978R

EDX Medical Group PLC

25 October 2023

EDX Medical Group plc

General Meeting

October 25, 2023

Result of General Meeting

The General Meeting of EDX Medical Group plc was held at the Roosevelt Room, Brown's Hotel, Albemarle Street, London, on 25 October 2023 at 2:00 p.m.

All three resolutions put to members were passed on a poll as ordinary resolutions.

The number of votes cast for and against each of the resolutions proposed, and the number of votes withheld were as follows:

 
  Resolution                       Votes for     %        Votes against   %      Votes withheld 
 Resolution 1 ( Ordinary 
  ) 
  To receive the Annual Report 
  and Accounts of the Company 
  for the financial year 
  ended 31 March 2023 together 
  with the Directors' reports 
  and auditor's report on 
  those accounts.                  149,949,300   100.00   0               0.00   0 
                                  ------------  -------  --------------  -----  --------------- 
 Resolution 2 ( Ordinary 
  ) 
  To re-appoint PKF Littlejohn 
  LLP as auditor of the Company 
  to hold office until the 
  conclusion of the next 
  general meeting at which 
  accounts are laid before 
  the Company.                     149,949,300   100.00   0               0.00   0 
                                  ------------  -------  --------------  -----  --------------- 
 Resolution 3 ( Ordinary 
  ) 
  To authorise the Directors 
  to determine the fees payable 
  to the auditor.                  149,949,300   100.00   0               0.00   0 
                                  ------------  -------  --------------  -----  ---------------

As at 25 October 2023, there were 300,965,909 ordinary shares in issue. Shareholders are entitled to one vote per share. Votes withheld are not votes in law and so have not been included in the calculation of the proportion of votes for and against a resolution.

The full text of each resolution is available in the Notice of General Meeting, published on our website.

About EDX Medical Group

EDX Medical Group plc develops innovative digital diagnostic products and services, enabling cost effective and timely delivery of personalised treatment for cancer, heart disease and infectious diseases. The company is listed on the AQSE Growth Market (TIDM: EDX).

EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with CEO, Dr Mike Hudson.

By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost-effectively improve the detection and characterisation of disease in order to personalise treatment in a timely fashion. Early disease detection and biologically-based personal treatment optimisation is considered to be the most impactful way of reducing deaths and lowering the cost of healthcare globally.

EDX Medical has established expertise in the design, development, validation and sourcing of diagnostic testing solutions to ISO 13485 and key laboratory tests performed by the Company have been accredited to ISO 15189 by the United Kingdom Accreditation Service (UKAS).

EDX Medical Group operates a molecular biology and diagnostics laboratory in Cambridge, UK, and 100%-owned subsidiary companies, Hutano Diagnostics Limited in Oxford, UK, and Torax Biosciences Ltd in Ireland.

Learn more: www.edxmedical.co.uk.

Contacts:

 
 EDX Medical plc 
 Dr Mike Hudson (Chief Executive 
  Officer)                             +44 (0)7812 345 301 
 
 Oberon Capital 
 Nick Lovering (Corporate Adviser) 
  Adam Pollock (Corporate Broking) 
  Mike Seabrook (Corporate Broking)    +44 (0)20 3179 5300 
 
 Media House International 
 Ramsay Smith                          +44 (0)7788 414856 
                                        ramsay@mediahouse.co.uk 
  Gary McQueen                          + 44 (0)7834 694609 
                                        gary@mediahouse.co.uk

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NEXMABJTMTITBLJ

(END) Dow Jones Newswires

October 25, 2023 10:00 ET (14:00 GMT)

EDX Medical (AQSE:EDX)
過去株価チャート
から 5 2024 まで 6 2024